

PROGRAM

WEDNESDAY 18 OCTOBER 2017

8:30 Workshop opening & HBV update

Session 1 Clinical Update on HBV Cure

- 8:35 **TAF – The latest update, which questions remain to be answered?**
Pietro Lampertico - University of Milan, Milan, Italy
- 8:50 **Hepatitis B Cure: From Discovery to Regulatory Endpoints in HBV clinical research: A summary of the AASLD/EASL statement**
Fabien Zoulim - INSERM, Paris, France
- 9:05 **Is immunomodulation really needed to cure HBV?**
Heiner Wedemeyer - Medical School Hannover, Hannover, Germany
- 9:20 Discussion

9:40 Coffee break

Session 2 New biomarkers: how will they help us?

- 10:10 **How to use new virological biomarkers to assess HBV cure: quantitative HBsAg, HBcrAg, HBV-RNA**
Florian Bömmel - University of Leipzig, Leipzig, Germany
- 10:25 **To look inside or outside of the liver for evidence of HBV cure?**
Georg Lauer - Massachusetts General Hospital, Boston, MA, USA
- 10:40 Discussion

Session 3 New Treatment modalities - Immunologic response

- 11:00 **How does HBV interact with the immune system**
Mala Maini - University College London, London, United Kingdom
- 11:15 **Innate Immunity : TLR, RIG-I, STING and potential others**
Adam Gehring - University of Toronto, Toronto, Canada
- 11:30 **Adaptive Immunity: Therapeutic vaccination, checkpoint inhibition and potential others**
Andre Boonstra (tbc) - Erasmus Medical Center, Rotterdam, the Netherlands
- 11:45 **Panel discussion**

12:15 Lunch

4th INTERNATIONAL HBV CURE WORKSHOP

TORONTO, CANADA • 18 OCTOBER 2017



Session 4 New Treatment modalities - Virological challenges

- 13:15 **Entry inhibition**
Stefan Urban - Heidelberg University, Heidelberg, Germany
- 13:25 **CCC – DNA inhibition**
Anuj Gaggar - Gilead Sciences, Foster City, USA
- 13:35 **RNA interference**
Bill Symonds - Arbutus, Burnaby, Canada
- 13:45 **Capsid inhibition**
Angela Lam (tbc) - Janssen, Doylestown, PA, USA
- 13:55 **HBV Ribonuclease H**
John Tavis - Saint Louis University School of Medicine, Saint Louis, MO, USA
- 14:05 **Other virologic mechanisms**
Stephen Locarnini - Victorian Infectious Diseases Reference Laboratory, Melbourne, Australia
- 14:15 **Roundtable discussion**

15:00 Coffee break

Session 5 From the science to the clinic

- 15:30 **Is personalized therapy needed to achieve success?**
Marion Peters - University of California, San Francisco, CA, USA
- 15:50 **Combination therapy how to navigate in a minefield of efficacy and toxicity?**
Jordan Feld - Toronto Centre for Liver Disease, Toronto, Canada
- 16:10 **Innovative trial design**
Henry Lik Yuen Chan - Chinese University of Hong Kong, Hong Kong
- 16:30 Round table discussion:
Trial design, treatment endpoints and regulatory approach
- 17:30 Closure of the Workshop

More information and registration:
www.virology-education.com
info@virology-education.com